The combination of ICIs and HER2-targeted ADC may be an innovative strategy for cancer treatment on account of the great benefits of atezolizumab plus T-DM1 in PD-L1-positive, HER2-positive advanced breast cancer and the rapid development of diverse anti-HER2 ADCs [76]. This evidence concerns the gene CD274 and cancer.